<VariationArchive VariationID="14655" VariationName="NM_000424.4(KRT5):c.1649del (p.Gly550fs)" VariationType="Deletion" Accession="VCV000014655" Version="14" RecordType="classified" NumberOfSubmissions="9" NumberOfSubmitters="7" DateLastUpdated="2024-05-19" DateCreated="2013-05-03" MostRecentSubmission="2024-03-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="29694" VariationID="14655">
      <GeneList>
        <Gene Symbol="KRT5" FullName="keratin 5" GeneID="3852" HGNC_ID="HGNC:6442" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="52514575" stop="52520394" display_start="52514575" display_stop="52520394" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52908358" stop="52914242" display_start="52908358" display_stop="52914242" Strand="-" />
          </Location>
          <OMIM>148040</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000424.4(KRT5):c.1649del (p.Gly550fs)</Name>
      <CanonicalSPDI>NC_000012.12:52515065:CCCCCC:CCCCC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12q13.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="52515066" stop="52515066" display_start="52515066" display_stop="52515066" variantLength="1" positionVCF="52515065" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52908850" stop="52908850" display_start="52908850" display_stop="52908850" variantLength="1" positionVCF="52908849" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>G550fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.52908855del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.52908855del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.52515071del" Assembly="GRCh38">
            <Expression>NC_000012.12:g.52515071del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008297.1" sequenceAccession="NG_008297" sequenceVersion="1" change="g.10394del">
            <Expression>NG_008297.1:g.10394del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000424.4" sequenceAccession="NM_000424" sequenceVersion="4" change="c.1649del" MANESelect="true">
            <Expression>NM_000424.4:c.1649del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000415.2" sequenceAccession="NP_000415" sequenceVersion="2" change="p.Gly550fs">
            <Expression>NP_000415.2:p.Gly550fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000424.4" sequenceAccession="NM_000424" sequenceVersion="4" change="c.1649delG" MANESelect="true">
            <Expression>NM_000424.4:c.1649delG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000424.3" sequenceAccession="NM_000424" sequenceVersion="3" change="c.1649delG">
            <Expression>NM_000424.3:c.1649delG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA216692" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="148040.0017" DB="OMIM" />
        <XRef Type="rs" ID="61126080" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000424.4(KRT5):c.1649del (p.Gly550fs) AND Epidermolysis bullosa simplex with migratory circinate erythema" Accession="RCV000015761" Version="31">
        <ClassifiedConditionList TraitSetID="4041">
          <ClassifiedCondition DB="MedGen" ID="C1836284">Epidermolysis bullosa simplex with migratory circinate erythema</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2004-09-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000424.4(KRT5):c.1649del (p.Gly550fs) AND not provided" Accession="RCV000056578" Version="8">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-10-23" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000424.4(KRT5):c.1649del (p.Gly550fs) AND Epidermolysis bullosa simplex" Accession="RCV001352788" Version="1">
        <ClassifiedConditionList TraitSetID="9444">
          <ClassifiedCondition DB="MedGen" ID="C0079298">Epidermolysis bullosa simplex</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2009-01-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000424.4(KRT5):c.1649del (p.Gly550fs) AND Epidermolysis bullosa simplex with mottled pigmentation" Accession="RCV001814959" Version="2">
        <ClassifiedConditionList TraitSetID="4038">
          <ClassifiedCondition DB="MedGen" ID="C0432316">Epidermolysis bullosa simplex with mottled pigmentation</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2004-09-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000424.4(KRT5):c.1649del (p.Gly550fs) AND KRT5-related disorder" Accession="RCV003894806" Version="1">
        <ClassifiedConditionList TraitSetID="90664">
          <ClassifiedCondition>KRT5-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-15" NumberOfSubmissions="9" NumberOfSubmitters="7" DateCreated="2013-05-03" MostRecentSubmission="2024-03-16">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12925204</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15324323</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15647384</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15982306</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20055872</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23889190</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24104543</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27730678</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9036937</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301543</ID>
          <ID Source="BookShelf">NBK1369</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="90664" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="70654" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">KRT5-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">KRT5-related condition</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="4038" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1162" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Epidermolysis bullosa simplex with mottled pigmentation</ElementValue>
                <XRef ID="Epidermolysis+Bullosa+Simplex+with+Mottled+Pigmentation/2581" DB="Genetic Alliance" />
                <XRef ID="254180002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SPECKLED HYPERPIGMENTATION WITH PUNCTATE PALMOPLANTAR KERATOSES AND CHILDHOOD BLISTERING</ElementValue>
                <XRef Type="MIM" ID="131960" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EPIDERMOLYSIS BULLOSA SIMPLEX 2F, WITH MOTTLED PIGMENTATION</ElementValue>
                <XRef Type="MIM" ID="131960" DB="OMIM" />
                <XRef Type="Allelic variant" ID="148040.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="148040.0017" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EBS with mottled pigmentation</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Speckled hyperpigmentation, palmo-plantar punctate keratoses and childhood blistering</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">EBS2F</ElementValue>
                <XRef Type="MIM" ID="131960" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EBS-MP</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9737" />
                <XRef ID="9737" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma. EBS is distinguished from other types of epidermolysis bullosa (EB) or non-EB skin fragility syndromes by the location of the blistering in relation to the dermal-epidermal junction. In EBS, blistering occurs within basal keratinocytes. The severity of blistering ranges from limited to hands and feet to widespread involvement. Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation. Rare EBS subtypes have been associated with additional clinical features including pyloric atresia, muscular dystrophy, cardiomyopathy, and/or nephropathy.</Attribute>
                <XRef ID="NBK1369" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301543</ID>
                <ID Source="BookShelf">NBK1369</ID>
              </Citation>
              <XRef ID="79397" DB="Orphanet" />
              <XRef ID="C0432316" DB="MedGen" />
              <XRef ID="MONDO:0007556" DB="MONDO" />
              <XRef Type="MIM" ID="131960" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4041" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1161" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Epidermolysis bullosa simplex 2E, with migratory circinate erythema</ElementValue>
                <XRef ID="MONDO:0012258" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Epidermolysis bullosa simplex with migratory circinate erythema</ElementValue>
                <XRef ID="Epidermolysis+Bullosa+Simplex/8318" DB="Genetic Alliance" />
                <XRef ID="716700003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EBS-migr</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma. EBS is distinguished from other types of epidermolysis bullosa (EB) or non-EB skin fragility syndromes by the location of the blistering in relation to the dermal-epidermal junction. In EBS, blistering occurs within basal keratinocytes. The severity of blistering ranges from limited to hands and feet to widespread involvement. Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation. Rare EBS subtypes have been associated with additional clinical features including pyloric atresia, muscular dystrophy, cardiomyopathy, and/or nephropathy.</Attribute>
                <XRef ID="NBK1369" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16990" />
                <XRef ID="16990" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301543</ID>
                <ID Source="BookShelf">NBK1369</ID>
              </Citation>
              <XRef ID="158681" DB="Orphanet" />
              <XRef ID="C1836284" DB="MedGen" />
              <XRef ID="MONDO:0012258" DB="MONDO" />
              <XRef Type="MIM" ID="609352" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9444" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9491" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Epidermolysis bullosa simplex</ElementValue>
                <XRef ID="MONDO:0017610" DB="MONDO" />
                <XRef ID="67144006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epidermolysis bullosa simplex, Weber-Cockayne type (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epidermolysis bullosa simplex, Dowling-Meara type (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epidermolysis bullosa simplex with mottled pigmentation (subtype)</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma. EBS is distinguished from other types of epidermolysis bullosa (EB) or non-EB skin fragility syndromes by the location of the blistering in relation to the dermal-epidermal junction. In EBS, blistering occurs within basal keratinocytes. The severity of blistering ranges from limited to hands and feet to widespread involvement. Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation. Rare EBS subtypes have been associated with additional clinical features including pyloric atresia, muscular dystrophy, cardiomyopathy, and/or nephropathy.</Attribute>
                <XRef ID="NBK1369" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10752" />
                <XRef ID="10752" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301543</ID>
                <ID Source="BookShelf">NBK1369</ID>
              </Citation>
              <XRef ID="304" DB="Orphanet" />
              <XRef ID="C0079298" DB="MedGen" />
              <XRef ID="MONDO:0017610" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS131760" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="147248" SubmissionDate="2012-07-31" DateLastUpdated="2013-10-19" DateCreated="2013-10-19">
        <ClinVarSubmissionID localKey="KRT5:c.1649_1649delG" />
        <ClinVarAccession Accession="SCV000087690" DateUpdated="2013-10-19" DateCreated="2013-10-19" Type="SCV" Version="1" SubmitterName="Epithelial Biology;  Institute of Medical Biology, Singapore" OrgID="500159" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>flagged submission</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>not provided</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <MethodType>not provided</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.3:c.1649_1649delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Comment DataSource="NCBI" Type="FlaggedComment">Reason: This record appears to be redundant with a more recent record from the same submitter.</Comment>
        <Comment DataSource="NCBI" Type="FlaggedComment">Notes: SCV000087690 appears to be redundant with SCV000087691.</Comment>
        <SubmissionNameList>
          <SubmissionName>HIFD-CURATED-RECORDS_2012_5_17</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="147249" SubmissionDate="2012-07-31" DateLastUpdated="2013-10-19" DateCreated="2013-10-19">
        <ClinVarSubmissionID localKey="KRT5:c.1649delG" />
        <ClinVarAccession Accession="SCV000087691" DateUpdated="2013-10-19" DateCreated="2013-10-19" Type="SCV" Version="1" SubmitterName="Epithelial Biology;  Institute of Medical Biology, Singapore" OrgID="500159" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>not provided</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <MethodType>not provided</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.3:c.1649delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>HIFD-CURATED-RECORDS_2012_5_17</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="36026" SubmissionDate="2022-02-02" DateLastUpdated="2022-02-05" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="148040.0017_EPIDERMOLYSIS BULLOSA SIMPLEX 2E, WITH MIGRATORY CIRCINATE ERYTHEMA" title="KRT5, 1-BP DEL, 1649G_EPIDERMOLYSIS BULLOSA SIMPLEX 2E, WITH MIGRATORY CIRCINATE ERYTHEMA" />
        <ClinVarAccession Accession="SCV000036026" DateUpdated="2022-02-05" DateCreated="2013-04-04" Type="SCV" Version="7" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2004-09-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">EBS with Migratory Circinate Erythema</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a Japanese girl with epidermolysis bullosa simplex with migratory circinate erythema (EBS2E; 609352) and in 3 affected members (a girl, her mother, and her maternal uncle) of an unrelated 3-generation Korean family, Gu et al. (2003) identified heterozygosity for a deletion mutation (1649delG) in exon 9 of the KRT5 gene, involving the V2 domain and predicted to cause a frameshift that would delay the termination codon and result in a protein 35 amino acids longer than the wildtype. The patients had a phenotype that was less severe than that of EBS Dowling-Meara, with an unusual migratory circinate erythema and multiple vesicles on the erythematous area. In both patients, the lesions healed without scarring but with brown pigmentation. The mother of the Korean girl had generalized hypopigmented and hyperpigmented patches on the trunk and extremities, but only occasional small vesicles in these same areas. All affected adults in this family had similar pigmentary changes. The mutation in the Japanese girl was assumed to have arisen de novo, as there were no other affected family members, and the mutation was not found in the DNA of blood samples from her parents.</Attribute>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <XRef DB="OMIM" ID="609352" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">When a younger sister with EBS was born into the Japanese family previously reported by Gu et al. (2003) and was found to have the same 1649delG mutation as her older sib, Nagao-Watanabe et al. (2004) reinvestigated the familial segregation of the mutation and identified heterozygosity for the deletion in the mother's DNA from hair bulb and buccal cell samples. Closer scrutiny of the mother's history revealed that she had migratory circinate pigmentation of the skin in childhood, and Nagao-Watanabe et al. (2004) concluded that this represented maternal somatic and germline mosaicism.</Attribute>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">15324323</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a 3-year-old Japanese girl with EBS with migratory circinate erythema, Kumagai et al. (2017) identified heterozygosity for a de novo occurrence of the c.1649delG mutation in the KRT5 gene. The authors noted that the migratory circinate erythema appeared in infancy and spontaneously resolved, and the patient then developed mottled pigmentation.</Attribute>
              <Citation>
                <ID Source="PubMed">27730678</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">EBS with Mottled Pigmentation</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In 2 affected members of a Japanese family with epidermolysis bullosa simplex with mottled pigmentation (EBS2F; 131960), Horiguchi et al. (2005) detected heterozygosity for a 1-basepair deletion (c.1649delG) in exon 9 of the KRT5 gene resulting in replacement of the C-terminal domain of the protein with an aberrant sequence of 76 amino acids very rich in alanine and proline residues that is 35 amino acids longer than wildtype. Horiguchi et al. (2005) noted that this mutation had previously been identified in patients with EBS with migratory circinate erythema (EBS2E; 609352) by Gu et al. (2003).</Attribute>
              <Citation>
                <ID Source="PubMed">15982306</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <XRef DB="OMIM" ID="131960" Type="MIM" />
              <XRef DB="OMIM" ID="609352" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In 2 Chinese sibs with EBS with mottled pigmentation (EBS2F) and in their affected mother, Tang et al. (2009) detected heterozygosity for the c.1649delG mutation in KRT5, resulting in frameshift and extension of the protein (Gly550AlafsTer77).</Attribute>
              <Citation>
                <ID Source="PubMed">20055872</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In an infant girl who exhibited EBS with mottled pigmentation (EBS2F; 131960), Geller et al. (2013) identified heterozygosity for the c.1649delG mutation in the KRT5 gene.</Attribute>
              <Citation>
                <ID Source="PubMed">23889190</ID>
              </Citation>
              <XRef DB="OMIM" ID="131960" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <Name>KRT5, 1-BP DEL, 1649G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 1649G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="148040.0017" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">EPIDERMOLYSIS BULLOSA SIMPLEX 2E, WITH MIGRATORY CIRCINATE ERYTHEMA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4202636" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="4906926|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002179518" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12925204</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15324323</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24104543</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15647384</ID>
          </Citation>
          <Comment>This sequence change results in a frameshift in the KRT5 gene (p.Gly550Alafs*77). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 41 amino acid(s) of the KRT5 protein and extend the protein by 35 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This frameshift has been observed in individual(s) with autosomal dominant epidermolysis bullosa simplex (PMID: 12925204, 15324323, 24104543). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 14655). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this frameshift affects KRT5 function (PMID: 15647384). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.52908850del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8791392" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="17988811|KRT5-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004714245" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" OrgAbbreviation="PG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The KRT5 c.1649delG variant is predicted to result in a frameshift and premature protein termination (p.Gly550Alafs*77). This variant is predicted to result in a frameshift and elongation of the protein beyond the normal stop codon (p.Gly550Alafs*77). This variant has been reported as a recurrent finding in individuals with epidermolysis bullosa simplex (see for example, Nagao-Watanabe et al. 2004. PubMed ID: 15324323; Kumagai et al. 2017. PubMed ID: 27730678; Table S1, Chen et al. 2020. PubMed ID: 32484238). It has been documented as a de novo variant, as well as inherited from a mosaic parent. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in KRT5 are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.3:c.1649delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">KRT5-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3046843" SubmissionDate="2021-03-10" DateLastUpdated="2021-03-28" DateCreated="2021-03-28">
        <ClinVarSubmissionID localKey="NM_000424.4:c.1649delG|Simplex epidermolysis bullosa" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001547418" DateUpdated="2021-03-28" DateCreated="2021-03-28" Type="SCV" Version="1" SubmitterName="Biomedical Innovation Departament, CIEMAT" OrgID="506581" OrganizationCategory="resource" OrgAbbreviation="BioINN" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2009-01-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9036937</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.Gly550Alafs*77</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.4:c.1649delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Simplex epidermolysis bullosa</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9245631</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1389820" SubmissionDate="2021-09-25" DateLastUpdated="2018-04-02" DateCreated="2018-04-02">
        <ClinVarSubmissionID localKey="GDXSV:154309" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000709814" DateUpdated="2018-04-02" DateCreated="2018-04-02" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-08-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein extension, replacing the last 41 amino acids with an elongated segment of 76 amino acids with different characteristics; Published functional studies demonstrates a damaging effect as in vitro expressed mutant K5 forms much shorter polymers with K14 than wildtype K5 with viscoelastic properties too weak to be reliably measured (Gu et al., 2005); In contrast to the typical hot spot mutations in KRT5 that affect the central rod domain, this variant is predicted to extend the tail domain of keratin 5 and completely alter its composition and physico-chemical properties; the extended tail region has been proposed to interfere with functional interactions between this keratin and its associated proteins (Gu et al., 2005); Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 20199538, 20055872, 27730678, 24104543, 23993914, 23889190, 15647384, 15982306, 28830826, 15324323, 12925204, 21375516, 32484238, 33274474)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:29946</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.3:c.1649del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_51_20210925044204</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4042815" SubmissionDate="2022-02-02" DateLastUpdated="2022-02-05" DateCreated="2022-01-26">
        <ClinVarSubmissionID localKey="148040.0017_EPIDERMOLYSIS BULLOSA SIMPLEX 2F, WITH MOTTLED PIGMENTATION" title="KRT5, 1-BP DEL, 1649G_EPIDERMOLYSIS BULLOSA SIMPLEX 2F, WITH MOTTLED PIGMENTATION" />
        <ClinVarAccession Accession="SCV002061891" DateUpdated="2022-02-05" DateCreated="2022-01-26" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2004-09-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">EBS with Migratory Circinate Erythema</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a Japanese girl with epidermolysis bullosa simplex with migratory circinate erythema (EBS2E; 609352) and in 3 affected members (a girl, her mother, and her maternal uncle) of an unrelated 3-generation Korean family, Gu et al. (2003) identified heterozygosity for a deletion mutation (1649delG) in exon 9 of the KRT5 gene, involving the V2 domain and predicted to cause a frameshift that would delay the termination codon and result in a protein 35 amino acids longer than the wildtype. The patients had a phenotype that was less severe than that of EBS Dowling-Meara, with an unusual migratory circinate erythema and multiple vesicles on the erythematous area. In both patients, the lesions healed without scarring but with brown pigmentation. The mother of the Korean girl had generalized hypopigmented and hyperpigmented patches on the trunk and extremities, but only occasional small vesicles in these same areas. All affected adults in this family had similar pigmentary changes. The mutation in the Japanese girl was assumed to have arisen de novo, as there were no other affected family members, and the mutation was not found in the DNA of blood samples from her parents.</Attribute>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <XRef DB="OMIM" ID="609352" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">When a younger sister with EBS was born into the Japanese family previously reported by Gu et al. (2003) and was found to have the same 1649delG mutation as her older sib, Nagao-Watanabe et al. (2004) reinvestigated the familial segregation of the mutation and identified heterozygosity for the deletion in the mother's DNA from hair bulb and buccal cell samples. Closer scrutiny of the mother's history revealed that she had migratory circinate pigmentation of the skin in childhood, and Nagao-Watanabe et al. (2004) concluded that this represented maternal somatic and germline mosaicism.</Attribute>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">15324323</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a 3-year-old Japanese girl with EBS with migratory circinate erythema, Kumagai et al. (2017) identified heterozygosity for a de novo occurrence of the c.1649delG mutation in the KRT5 gene. The authors noted that the migratory circinate erythema appeared in infancy and spontaneously resolved, and the patient then developed mottled pigmentation.</Attribute>
              <Citation>
                <ID Source="PubMed">27730678</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">EBS with Mottled Pigmentation</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In 2 affected members of a Japanese family with epidermolysis bullosa simplex with mottled pigmentation (EBS2F; 131960), Horiguchi et al. (2005) detected heterozygosity for a 1-basepair deletion (c.1649delG) in exon 9 of the KRT5 gene resulting in replacement of the C-terminal domain of the protein with an aberrant sequence of 76 amino acids very rich in alanine and proline residues that is 35 amino acids longer than wildtype. Horiguchi et al. (2005) noted that this mutation had previously been identified in patients with EBS with migratory circinate erythema (EBS2E; 609352) by Gu et al. (2003).</Attribute>
              <Citation>
                <ID Source="PubMed">15982306</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">12925204</ID>
              </Citation>
              <XRef DB="OMIM" ID="131960" Type="MIM" />
              <XRef DB="OMIM" ID="609352" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In 2 Chinese sibs with EBS with mottled pigmentation (EBS2F) and in their affected mother, Tang et al. (2009) detected heterozygosity for the c.1649delG mutation in KRT5, resulting in frameshift and extension of the protein (Gly550AlafsTer77).</Attribute>
              <Citation>
                <ID Source="PubMed">20055872</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In an infant girl who exhibited EBS with mottled pigmentation (EBS2F; 131960), Geller et al. (2013) identified heterozygosity for the c.1649delG mutation in the KRT5 gene.</Attribute>
              <Citation>
                <ID Source="PubMed">23889190</ID>
              </Citation>
              <XRef DB="OMIM" ID="131960" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KRT5" />
          </GeneList>
          <Name>KRT5, 1-BP DEL, 1649G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 1649G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="148040.0017" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">EPIDERMOLYSIS BULLOSA SIMPLEX 2F, WITH MOTTLED PIGMENTATION</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="40663" SubmissionDate="2013-04-30" DateLastUpdated="2022-10-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="NM_000424.3:c.1649delG_NBK1369" title="NM_000424.3:c.1649delG and Epidermolysis Bullosa Simplex" />
        <ClinVarAccession Accession="SCV000040663" DateUpdated="2022-10-01" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">12925204</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="PubMed">15324323</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="PubMed">20301543</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="BookShelf">NBK1369</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <Purpose>Assert pathogenicity</Purpose>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="61126080" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000424.3:c.1649delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1836284" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4202636" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="40663" TraitType="Disease" MappingType="XRef" MappingValue="C1836284" MappingRef="MedGen">
        <MedGen CUI="C1836284" Name="Epidermolysis bullosa simplex with migratory circinate erythema" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8791392" TraitType="Disease" MappingType="Name" MappingValue="KRT5-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="KRT5-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="147249" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3046843" TraitType="Disease" MappingType="Name" MappingValue="Simplex epidermolysis bullosa" MappingRef="Preferred">
        <MedGen CUI="C0079298" Name="Epidermolysis bullosa simplex" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="147248" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4042815" TraitType="Disease" MappingType="Name" MappingValue="EPIDERMOLYSIS BULLOSA SIMPLEX 2F, WITH MOTTLED PIGMENTATION" MappingRef="Alternate">
        <MedGen CUI="C0432316" Name="Epidermolysis bullosa simplex with mottled pigmentation" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="36026" TraitType="Disease" MappingType="Name" MappingValue="EPIDERMOLYSIS BULLOSA SIMPLEX 2E, WITH MIGRATORY CIRCINATE ERYTHEMA" MappingRef="Preferred">
        <MedGen CUI="C1836284" Name="Epidermolysis bullosa simplex with migratory circinate erythema" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1389820" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

